Literature DB >> 7942158

Bone formation by marrow osteogenic cells (MBA-15) is not accompanied by osteoclastogenesis and generation of hematopoietic supportive microenvironment.

D Benayahu1, O Gurevitch, D Zipori, S Wientroub.   

Abstract

This study was aimed at elucidating the relationship between osteogenic activity of marrow stromal cells and their ability to support hematopoiesis followed by the bone-remodeling process. We used the MBA-15 cell line, which expresses osteoblastic phenotype in vitro and forms bone in diffusion chamber. We have compared bone formation and hematopoietic responses elicited in vivo by these cells with the implantation of freshly isolated bone marrow cells (BMC) or demineralized tooth matrix (DTM). Both MBA-15 cells and BMC, implanted under the kidney capsule, yielded intramembraneous bone, but DTM, implanted subcutaneously, elicited endochondral bone. MBA-15 formed primary bone, mimicking only the initial sequential stages of the ossification process. Neither histologic signs of bone resorption and remodeling nor tartrate-resistant acid phosphatase (TRAP)-positive cells and marrow formation were observed. Bone formation was monitored biochemically. Functions for hematopoietic stem and committed cell content were measured by GM-CFU and BFU-E assays that confirmed the morphologic observations. In both BMC and DTM implantation, bone formation was followed by hematopoietic activity, osteoclastogenesis, and remodeling. We conclude that MBA-15 osteoprogenitor cells, despite their extensive bone formation ability, are unable to form a microenvironment supportive for hematopoiesis and osteoclastogenesis or to initiate bone remodeling.

Entities:  

Mesh:

Year:  1994        PMID: 7942158     DOI: 10.1002/jbmr.5650090719

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  3 in total

1.  Stable changes in mesenchymal stromal cells from multiple myeloma patients revealed through their responses to Toll-like receptor ligands and epidermal growth factor.

Authors:  Meirav Pevsner-Fischer; Sarit Levin; Tal Hammer-Topaz; Yifat Cohen; Felix Mor; Gerard Wagemaker; Arnon Nagler; Irun Robert Cohen; Dov Zipori
Journal:  Stem Cell Rev Rep       Date:  2012-06       Impact factor: 5.739

2.  Mineralization of marrow-stromal osteoblasts MBA-15 on three-dimensional carriers.

Authors:  D Benayahu; R Kompier; A Shamay; A Kadouri; D Zipori; S Wientroub
Journal:  Calcif Tissue Int       Date:  1994-08       Impact factor: 4.333

3.  Biotechnological approach for systemic delivery of membrane Receptor Activator of NF-κB Ligand (RANKL) active domain into the circulation.

Authors:  Alfredo Cappariello; Riccardo Paone; Antonio Maurizi; Mattia Capulli; Nadia Rucci; Maurizio Muraca; Anna Teti
Journal:  Biomaterials       Date:  2015-01-17       Impact factor: 12.479

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.